4//SEC Filing
Fundaro Paolo 4
Accession 0001140361-20-018617
CIK 0001270073other
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 8:06 PM ET
Size
10.4 KB
Accession
0001140361-20-018617
Insider Transaction Report
Form 4
Fundaro Paolo
Director
Transactions
- Sale
Common stock, par value $0.001 per share
2020-08-17$46.75/sh−1,235,512$57,760,186→ 4,000,000 total(indirect: See Footnote) - Sale
Common stock, par value $0.001 per share
2020-08-13$52.60/sh−83,000$4,365,451→ 5,417,000 total(indirect: See Footnote) - Sale
Common stock, par value $0.001 per share
2020-08-14$50.55/sh−54,600$2,760,112→ 5,362,400 total(indirect: See Footnote) - Sale
Common stock, par value $0.001 per share
2020-08-17$50.15/sh−126,888$6,362,913→ 5,235,512 total(indirect: See Footnote)
Holdings
- 21,028
Common stock, par value $0.001 per share
Footnotes (2)
- [F1]These shares are held by Genextra S.p.A. Mr. Fundaro is the Chief Executive Officer of Genextra S.p.A. and, in such capacity, Mr. Fundaro exercises voting control over the shares of common stock owned by Genextra S.p.A and investment control over such shares as authorized by the board of Genextra S.p.A. Mr. Fundaro disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
- [F2]Genextra S.p.A. will apply the proceeds from the sales to pay off outstanding indebtedness under its margin loan secured by its shares of Intercept's common stock, and for general corporate purposes.
Documents
Issuer
INTERCEPT PHARMACEUTICALS, INC.
CIK 0001270073
Entity typeother
Related Parties
1- filerCIK 0001559537
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 8:06 PM ET
- Size
- 10.4 KB